June 8, 2022 — Take that, Omicron. Outcomes of a trial a mix COVID-19 vaccine booster reveals a “sturdy antibody response” in opposition to the Omicron variant, vaccine producer Moderna introduced Wednesday.
The neutralizing antibody response was eight occasions larger at 1 month following a 50-mcg dose with the booster containing each the unique mRNA-1273 vaccine and a brand new vaccine in improvement that particularly targets the Omicron variant.
The bivalent vaccine, mRNA-1273.214, was in comparison with a 50-mcg dose of the unique vaccine alone in 473 seronegative individuals within the Section 2/3 trial.
These outcomes provide promise of larger safety in opposition to Omicron following earlier experiences that confirmed that current COVID-19 vaccines weren’t as efficient in opposition to the Omicron variant.
Security and tolerability of the brand new vaccine was per a previous booster dose of the unique vaccine, the corporate reported.
Moderna additionally has a bivalent vaccine booster in improvement that features the unique vaccine and a vaccine particular to the Beta variant of SARS-CoV-2, the virus that causes COVID-19.
Moderna plans to file this new information with the FDA as a part of its software requesting authorization.
“We anticipate extra sturdy safety in opposition to variants of concern with mRNA-1273.214, making it our lead candidate for a Fall 2022 booster,” Stephane Bancel, chief govt officer at Moderna, mentioned in an organization information launch. “We’re submitting our preliminary information and evaluation to regulators with the hope that the Omicron-containing bivalent booster might be obtainable within the late summer season.”
